Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor.

ABSTRACT: Breast cancer remains the leading cause of cancer-related deaths in women. Therefore, developing targeted combination therapies that improve overall survival in breast cancer patients continues to pose a major clinical challenge. Etoposide (ETO), a topoisomerase II inhibitor that induces transient double-strand breaks by blocking the cleavable complex, is currently used in high doses to treat radioresistant or metastatic breast cancers. To enhance the effectiveness of radiation and chemotherapy, targeting molecular mechanisms involved in DNA repair of induced DNA lesions could selectively increase tumor cell death. Since the effects of ETO are primarily seen during the S/G2 phases of the cell cycle, its efficacy could potentially be enhanced by using an inhibitor of a DNA repair gene invol

SUBMITTER: Kumar ARK 

PROVIDER: S-EPMC12818603 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature